The Use of Antipsychotics in the Program of All-inclusive Care for the Elderly (PACE)

Antipsychotic Use Within the Program of All-inclusive Care for the Elderly (PACE)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03692182

Enrollment

10000

Registered

2018-10-02

Start date

2017-01-31

Completion date

2019-03-31

Last updated

2019-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavioral and Psychiatric Symptoms of Dementia

Keywords

Antipsychotic, Dementia

Brief summary

The aim of this study is to retrospectively evaluate and describe the use of antipsychotics among participants enrolled in the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.

Detailed description

Much national attention has been given to assessing and reducing the use of antipsychotics among nursing home residents, yet comparatively little attention has focused on antipsychotic use among older adults receiving care in community-based settings. The primary objective of this study is to determine the prevalence of antipsychotic use among a nationally representative sample of nursing home-eligible older adults in a community-based practice setting known as Program of All-inclusive Care for the Elderly (PACE). The secondary objectives are focused on characterizing antipsychotic use within PACE and for these participants. Specifically, the investigator's secondary objectives are to describe patterns of other drugs concomitantly used with antipsychotics (e.g., benzodiazepines, opioids) and to identify clinically relevant drug-drug interactions involving antipsychotics.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participant enrolled in PACE contractually receiving pharmacy services from Tabula Rasa Healthcare CareKinesis Pharmacy (Tabula Rasa HealthCare) during the project time period (January 2017 through December 2017).

Exclusion criteria

* Participant with a diagnosis of bipolar disorder and/or schizophrenia, according to pharmacy records.

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of Antipsychotic Use	12 months	Quantitative description of antipsychotic use as assessed by pharmacy records

Secondary

Measure	Time frame	Description
Concomitant Drug Use with Antipsychotics	12 months	Qualitative and quantitative description of patterns of other drugs concomitantly used with antipsychotics as assessed by pharmacy records
Drug-Drug Interactions	12 months	Qualitative and quantitative description of drug-drug interactions involving antipsychotics as assessed by proprietary clinical decision support system (CDSS)

Countries

United States

Outcome results